Search

Acrizanib

Acrizanib is under investigation in clinical trial NCT02355028 (LHA510 Proof-of-concept Study as a Maintenance Therapy for Patients With Wet Age-related Macular Degeneration).

Bentonite

N,N'-diphenyl-1,4-phenylenediamine

MVC-COV1901

Medigen has combined forces with Dynavax, which offers an advanced adjuvant, CpG 1018 (also known as [ISS-1018]), for use with its vaccine. … As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210).

Epigallocatechin gallate

Epigallocatechin gallate has been investigated for the treatment of Hypertension and Diabetic Nephropathy.

Otelixizumab

Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis. … Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling.

CoviGlobulin

CoviGlobulin, a rabbit polyclonal antibody, was specifically designed as a potential therapy for COVID-19. … The antibodies themselves are produced in response to an immunogen and derived from antibody-producing plasma cells that were once B-cell clones.

AR-9281

AR-9281 inhibits soluble epoxide hydrolase.

Pipequaline

Pipequaline is an anticonflict & anticonvulsant quinoline derivative. It is an anxiolytic drug that was never marketed. … Due to these differences, this drug is classified as a nonbenzodiazepine anxiolytic.

Proguanil

It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. … Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells.